Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection

World Journal of Gastroenterology

Volumn 19, Issue 48, 2013, Pages 9377-9382

  Celen, Mustafa Kemal ^a   Mert, Duygu ^b   Ay, Müzeyyen ^c   Dal, Tuba ^a   Kaya, Safak ^d   Yildirim, Necmettin ^e   Gulsun, Serda ^f   Barcin, Tunga ^g   Kalkanli, Sevgi ^a   Dal, Mehmet Sinan ^a   Ayaz, Celal ^a  

^a DICLE UNIVERSITY   (Turkey)

^b Infectious Diseases Clinic State Hospital   (Turkey)

^c Midyat State Hospital   (Turkey)

^d Department of Infectious Disease   (Turkey)

^e Kiziltepe State Hospital   (Turkey)

^f Diyarbakir Devlet Hastanesi   (Turkey)

^g Mardin Park Hastanesi   (Turkey)

Author keywords

Chronic; Hepatitis B; Reverse transcriptase inhibitors; Tenofovir; Vertical transmission

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; TENOFOVIR DISOPROXIL;

ADULT; ANEMIA; ARTICLE; BIRTH WEIGHT; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FEMALE; GROWTH RETARDATION; HEART ARRHYTHMIA; HEPATITIS B; HUMAN; PREGNANCY; PREGNANCY DIABETES MELLITUS; PROTEINURIA; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VAGINITIS; VERTICAL TRANSMISSION; YOUNG ADULT;

CHRONIC; HEPATITIS B; REVERSE TRANSCRIPTASE INHIBITORS; TENOFOVIR; VERTICAL TRANSMISSION;

ADENINE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULINS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; ORGANOPHOSPHONATES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TURKEY; VIRAL LOAD;

EID: 84891460915     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i48.9377     Document Type: Article

References (30)

1. Petersen J. HBV treatment and pregnancy. J Hepatol 2011; 55: 1171-1173 [PMID: 21718670 DOI: 10.1016/j.jhep.2011.06.007]
2. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55: 1215-1221 [PMID: 21703206]
3. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859 [PMID: 9197213 DOI:10.1056/NEJM199706263362602]
4. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, Chen DS. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287-1293 [PMID: 17433322 DOI: 10.1053/j.gastro.2007.02.055]
5. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006; (2): CD004790 [PMID: 16625613 DOI: 10.1002/14651858. CD004790.pub2]
6. Farmer K, Gunn T, Woodfield DG. A combination of hepatitis B vaccine and immunoglobulin does not protect all infants born to hepatitis B e antigen positive mothers. N Z Med J 1987; 100: 412-414 [PMID: 2967932]
7. Grosheide PM, del Canho R, Heijtink RA, Nuijten AS, Zwijnenberg J, Bänffer JR, Wladimiroff YW, Botman MJ, Mazel JA, de Gast GC. Passive-active immunization in infants of hepatitis Be antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization. Am J Dis Child 1993; 147: 1316-1320 [PMID: 8249953]
8. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170: 1418-1423 [PMID: 7995980 DOI: 10.1093/infdis/170.6.1418]
9. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, Gerards LJ, de Gast GC, Fetter WP, Zwijneberg J, Schalm SW. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15: 1624-1630 [PMID: 9364693 DOI: SO264-410X(97)00080-7]
10. Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009; 29 Suppl 1: 133-139 [PMID: 19207977 DOI:10.1111/j.1478-3231.2008.01933.x]
11. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, Maley MW, Ayres A, Locarnini SA, Levy MT. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190: 489-492 [PMID: 19413519]
12. Jenh AM, Thio CL, Pham PA. Tenofovir for the Treatment of Hepatitis B Virus. Pharmacotherapy 2009; 29: 1212-1227 [PMID: 19792994]
13. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/ hep.23190]
15. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, Ghany MG, Reddy KR. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012; 57: 2423-2429 [PMID: 22543886 DOI:10.1007/s10620-012-2187-3]
16. Nurutdinova D, Overton ET. A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV. Expert Opin Drug Saf 2009; 8: 683-694 [PMID: 19715450 DOI: 10.1517/14740330903241584]
17. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, Anzidei G, Fiscon M, Alberico S, Martinelli P, Placido G, Guaraldi G, Pinnetti C, Floridia M. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 2009; 23: 513-520 [PMID: 19530956 DOI: 10.1089/apc.2008.0263]
18. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med 2009; 10: 397-406 [PMID: 19459986 DOI: 10.1111/j.1468-1293.2009.00709.x]
19. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19: e18-e25 [PMID: 22239517 DOI: 10.1111/j.1365-2893.2011.01492.x]
20. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103 [PMID: 19175878 DOI: 10.1111/j.1365-2893.2008.01056.x]
21. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455 [PMID: 19052126 DOI: 10.1056/NEJMoa0802878]
22. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Threeyear efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143 [PMID: 20955704 DOI: 10.1053/j.gastro.2010.10.011]
23. The Antiretroviral Pregnancy Registry: Interim Report for 1 January 1989 to 31 January 2011. Available from: URL: http://www. apregistry.com
24. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 147-159 [PMID: 20567182 DOI: 10.1097/ AOG.0b013e3181e45951]
25. Mi LJ, Karsdon J, Huang WM, Manheimer F, Zhang JH, Tran T, Brown RS, Ghany MG. Outcomes of eight Chinese-Americans pregnant patients with chronic hepatitis B (CHB) treated with tenofovir DF (TDF) during pregnancy. AASLD Annual Meeting, 1995-09-01. Available from: URL: http://trs.scivee. tv/node/1202
26. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29: 207-220 [PMID: 11873070]
27. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, De-Carlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118: e711-e718 [PMID: 16923923 DOI: 10.1542/ peds.2005-2525]
28. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152: 582-584 [PMID: 18346519 DOI: 10.1016/j.jpeds.2007.12.020]
29. Giles M, Visvanathan K, Sasadeusz J. Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding. Antivir Ther 2011; 16: 621-628 [PMID: 21817183 DOI: 10.3851/ IMP1813]
30. Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 2008; 42: 1581-1585 [PMID: 18957630 DOI: 10.1345/aph.1L083]